🩺 Therapie
bariatric / metabolic surgery
Weight-loss/metabolic surgery (gastric bypass, sleeve gastrectomy). Strong evidence for durable weight loss, type-2-diabetes remission (which can wane over years), and lower mortality, cardiovascular events, and cancer. Trade-offs: lifelong micronutrient deficiencies, and gastric bypass raises the risk of alcohol-use disorder.
7 well-supported · 0 disputed. This shows how settled each sub-question is, not whether bariatric / metabolic surgery is "good." Direction lives in each claim below.
The 7 claims about bariatric / metabolic surgery
Each keeps its own verdict — we never average them away.
Does gastric bypass increase alcohol use disorder risk?
Strong support Yes—RYGB (more than sleeve) raises new-onset AUD risk, with altered ethanol pharmacokinetics, higher AUD prevalence, and elevated alcohol-related liver disease/mortality.
Does bariatric surgery reduce cardiovascular events?
Strong support Yes—observational cohorts and meta-analyses consistently show ~40-50% lower MACE/MI, though no dedicated CV-outcome RCT and residual confounding remain.
Does bariatric surgery reduce all-cause mortality?
Strong support Yes—consistent observational and IPD-meta evidence shows ~25-50% lower all-cause mortality, though no dedicated mortality RCT exists.
Does bariatric surgery cause micronutrient deficiencies?
Strong support Yes—iron, B12, vitamin D, calcium and related deficiencies (and anemia/secondary hyperparathyroidism) are common post-op, malabsorptive procedures worse, supplementation mandatory.
Does metabolic surgery cause type 2 diabetes remission?
Strong support Yes—RCTs and cohorts show surgery causes far higher T2D remission than medical therapy, but remission wanes over time and relapse is common.
Does bariatric surgery produce durable long-term weight loss vs non-surgical care?
Strong support Yes—surgery yields large weight loss sustained for 10-20yr far exceeding non-surgical care, though partial regain and procedure-dependent durability are real.
Does bariatric surgery reduce cancer incidence?
Strong support Yes for obesity-associated cancers—large cohorts and metas show ~30-40% lower incidence, strongest in women/hormone-related cancers; evidence is observational.
Educational only, not medical advice. Hub descriptions are curated for honesty; see the methodology.